Patent: 5,955,425
✉ Email this page to a colleague
Summary for Patent: 5,955,425
Title: | Parathyroid hormone analogues for the treatment of osteoporosis |
Abstract: | This invention describes analogs of human parathyroid hormone which have increased activities in bone restoration, and increased bioavailabilities. The peptides described are derivatives of hPTH-(1-31) which have lactams formed for example, between either Glu.sup.22 and Lys.sup.26 or Lys.sup.26 and Asp.sup.30. In addition, the natural Lys.sup.27 may be substituted by either a Leu or other hydrophobic residues, such as Ile, norleucine, Met, Val, Ala, Trp, or Phe. Typically, these analogs have enhanced abilities to stimulate adenylyl cyclase in rat osteosarcoma cells, and show increased activities in bone restoration, using the ovariectomized rat model. The analogs also show enhanced activities and bioavailabilities, as demonstrated by their hypotensive effects in the rat. |
Inventor(s): | Morley; Paul (Ottawa, CA), Neugebauer; Witold (Ottawa, CA), Ross; Virginia J. S. (Gloucester, CA), Whitfield; James F. (Ottawa, CA), Willick; Gordon E. (Orleans, CA), Barbier; Jean-Rene (Gatineau, CA) |
Assignee: | National Research Council of Canada (CA) |
Application Number: | 08/691,647 |
Patent Claims: | see list of patent claims |
Details for Patent 5,955,425
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Nps Pharmaceuticals, Inc. | NATPARA | parathyroid hormone | For Injection | 125511 | 01/23/2015 | ⤷ Try a Trial | 2014-06-20 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |